Description
Pivikto 150 MG (Alpelisib) is a selective, orally bioavailable small-molecule inhibitor of the alpha isoform of class I phosphatidylinositol 3-kinase (PI3Kα), encoded by the PIK3CA gene a targeted antineoplastic agent that competitively inhibits PI3Kα kinase activity by occupying the ATP-binding pocket of the p110α catalytic subunit, thereby blocking phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), suppressing downstream AKT phosphorylation and mTOR complex activation, and halting PI3K/AKT/mTOR-driven tumor cell proliferation, survival, and endocrine therapy resistance in hormone receptor-positive (HR+), HER2-negative breast cancer cells harboring activating PIK3CA mutations supplied as 150 mg film-coated tablets, 28 tablets per pack, India-market packaging, and manufactured by Novartis.
Alpelisib, the active pharmaceutical ingredient of Pivikto, is approved in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen establishing alpelisib as the first PI3Kα inhibitor to receive regulatory approval in breast cancer and as the foundational targeted combination partner with fulvestrant for PIK3CA-mutated HR+/HER2− metastatic breast cancer, a molecular subtype representing approximately 40% of all HR+/HER2− advanced breast cancer cases.
The recommended dose of Pivikto (Alpelisib) is 300 mg (two 150 mg tablets) orally once daily with food, administered continuously in combination with fulvestrant 500 mg administered intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent 28-day cycle; premenopausal and perimenopausal women must also receive a gonadotropin-releasing hormone (GnRH) agonist in combination with alpelisib and fulvestrant. The pivotal Phase 3 SOLAR-1 trial (NCT02437318; n=572 total; PIK3CA-mutated cohort n=341) established alpelisib plus fulvestrant as the standard of care for PIK3CA-mutated HR+/HER2− advanced breast cancer, achieving a median progression-free survival (PFS) of 11.0 months versus 5.7 months with fulvestrant plus placebo (hazard ratio [HR] 0.65; 95% CI 0.50–0.85; p<0.001; 35% reduction in the risk of disease progression or death) the first Phase 3 trial to demonstrate a statistically significant PFS benefit by targeting the PI3Kα pathway in PIK3CA-mutated HR+/HER2− metastatic breast cancer.
Important: PIK3CA mutation testing using an FDA-approved companion diagnostic the therascreen PIK3CA RGQ PCR Kit (tissue or plasma) or FoundationOne CDx (tissue) is mandatory before initiating alpelisib; patients must have confirmed PIK3CA mutation status to be eligible for alpelisib treatment. Alpelisib carries a risk of severe hyperglycemia (Grade 3–4 blood glucose elevation ≥250 mg/dL occurred in approximately 37% of patients in SOLAR-1); assess fasting plasma glucose (FPG) and HbA1c before initiating alpelisib and monitor at least weekly for the first 2 weeks, then at least once every 4 weeks; manage hyperglycemia with antihyperglycemic agents (metformin is the preferred first-line agent) and alpelisib dose reductions as required; patients with Type 2 diabetes mellitus or HbA1c ≥5.7% at baseline are at substantially increased risk of severe hyperglycemia and require optimized glycemic management before and during treatment.
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with alpelisib; monitor patients for new or worsening skin reactions and permanently discontinue alpelisib for confirmed severe cutaneous reactions. Severe diarrhea occurred in 6.7% of patients receiving alpelisib in SOLAR-1; manage with antidiarrheal agents and alpelisib dose modifications. Pneumonitis, including fatal cases, has been reported with alpelisib; evaluate patients with new or worsening respiratory symptoms; permanently discontinue alpelisib for Grade 3 or 4 pneumonitis.
Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported; permanently discontinue alpelisib for anaphylaxis or anaphylactic shock. The most common adverse reactions (≥20%) with alpelisib in SOLAR-1 were hyperglycemia (63.7%), diarrhea (57.7%), rash (52.1%), nausea (45.2%), fatigue (42.0%), decreased appetite (35.9%), stomatitis (29.9%), vomiting (27.5%), weight decreased (26.8%), and decreased hemoglobin (21.4%). Do not substitute alpelisib for other PI3K, AKT, or mTOR inhibitors without confirmed indication-specific prescribing and PIK3CA mutation biomarker verification. Searching for Pivikto 150 MG Alpelisib? Mediaid Pharmacy lists this product across its oncology medicines, breast cancer medicines, and Novartis medicines portfolios and ships it worldwide.
Basic Product Information of Pivikto 150 MG (Alpelisib)
| Brand Name | Pivikto 150 MG (Alpelisib) India-market packaging; also marketed globally as Piqray (alpelisib) by Novartis in multiple international markets |
| Product Name | Pivikto (India-market brand name for alpelisib tablets by Novartis) |
| Generic Name | Alpelisib (INN; also designated BYL719 during development; a selective, orally bioavailable inhibitor of the alpha isoform of class I phosphatidylinositol 3-kinase [PI3Kα], encoded by PIK3CA; alpelisib competitively occupies the ATP-binding site of the p110α catalytic subunit of PI3Kα, blocking phosphorylation of PIP2 to PIP3, thereby suppressing PDK1-mediated phosphorylation of AKT at Thr308 and mTORC2-mediated phosphorylation of AKT at Ser473, with consequent inhibition of mTORC1, S6 kinase, and 4E-BP1 collectively shutting down PI3K/AKT/mTOR pathway-driven tumor cell proliferation and survival; PIK3CA activating mutations [helical domain: E542K, E545K; kinase domain: H1047R; and others] render PI3Kα constitutively active and are present in approximately 38–40% of HR+/HER2− advanced breast cancer tumors, conferring endocrine therapy resistance; alpelisib selectively inhibits PI3Kα over the PI3Kβ, PI3Kγ, and PI3Kδ isoforms, reducing off-target immunosuppressive and metabolic effects; developed and commercialized by Novartis; FDA approval for HR+/HER2−, PIK3CA-mutated, advanced or metastatic breast cancer in combination with fulvestrant: May 24, 2019) |
| Drug Class | PI3Kα (Phosphatidylinositol 3-Kinase Alpha) Inhibitor; Selective Class I PI3K Alpha Isoform Kinase Inhibitor; Oral Small-Molecule Kinase Inhibitor; PI3K/AKT/mTOR Pathway Inhibitor (PI3Kα Node); PIK3CA-Mutated Breast Cancer Targeted Therapy; HR+/HER2-Negative Metastatic Breast Cancer Targeted Oral Medicine; Hormone Receptor-Positive Breast Cancer Kinase Inhibitor; Endocrine Therapy Resistance Reversal Agent; Antineoplastic Targeted Agent; Original Molecule Oncology Oral Tablet; Post-CDK4/6 Inhibitor or Post-Aromatase Inhibitor Metastatic Breast Cancer Therapy; Fulvestrant Combination Partner; PIK3CA Companion Diagnostic-Required Precision Oncology Medicine |
| Formulation | Film-coated tablets for oral administration take with food (a meal) to reduce nausea and improve gastrointestinal tolerability; swallow whole do not crush, chew, or split tablets; take at approximately the same time each day; if a dose is missed, take it within 9 hours of the scheduled time, then resume the regular daily schedule if more than 9 hours have passed, skip the missed dose and take the next dose at the regularly scheduled time the following day; if vomiting occurs after a dose, do not take an additional dose on that day take the next dose at the scheduled time the next day; administer alpelisib in combination with fulvestrant 500 mg IM (Days 1, 15 of Cycle 1, then Day 1 of each 28-day cycle thereafter); premenopausal and perimenopausal women must also receive a GnRH agonist concurrently |
| Available Strengths | 150 mg film-coated tablets per tablet the recommended daily dose of alpelisib is 300 mg once daily, requiring two 150 mg tablets per dose; the 150 mg tablet strength allows dose reductions to 250 mg daily (via combination with 50 mg tablets where available, or per local prescribing guidance) or 200 mg daily in the event of toxicity; dose reductions are implemented for Grade 3 or 4 adverse reactions including severe hyperglycemia, severe diarrhea, and severe cutaneous reactions; alpelisib should not be dose-reduced below 200 mg daily permanently discontinue if Grade 3 or 4 toxicity recurs at 200 mg; body-weight-based dose adjustment is not required; no dose adjustment is required for mild or moderate renal or hepatic impairment; pharmacokinetic data do not support dose adjustment solely based on age in patients ≥65 years |
| Available Pack Size | 28 tablets per pack (India-market packaging); at the recommended dose of 300 mg once daily (two 150 mg tablets per day), one 28-tablet pack supplies 14 days of therapy; for a complete 28-day treatment cycle, two 28-tablet packs are required per patient per month; hospital pharmacies, oncology treatment centers, and patient access programs typically procure Pivikto 150 MG on a per-cycle or monthly basis corresponding to the 28-day continuous daily dosing schedule; institutions managing multiple patients on alpelisib simultaneously typically calculate monthly procurement by multiplying the number of active patients by two 28-tablet packs per patient per 28-day cycle; procurement planning should account for potential dose reductions and treatment interruptions that may reduce per-cycle tablet consumption in some patients |
| Dosing Schedule | Recommended Dose: Alpelisib 300 mg (two 150 mg tablets) orally once daily with food, administered continuously on a 28-day cycle. Combination Partner: Fulvestrant 500 mg administered intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of each 28-day cycle thereafter; premenopausal and perimenopausal women must receive concurrent GnRH agonist therapy (e.g., goserelin, leuprolide). Duration: Continue until disease progression or unacceptable toxicity. Dose Reductions for Toxicity: First dose reduction: 250 mg once daily; second dose reduction: 200 mg once daily; permanently discontinue alpelisib if Grade 3 or 4 adverse reactions persist at the 200 mg dose level or recur after two dose reductions. Mandatory Safety Assessments Before and During Treatment: Confirm PIK3CA mutation status using an FDA/EMA-approved companion diagnostic (therascreen PIK3CA RGQ PCR Kit or FoundationOne CDx) before initiating alpelisib; assess fasting plasma glucose (FPG) and HbA1c at baseline optimize glycemic control before initiating alpelisib in patients with pre-existing hyperglycemia or HbA1c ≥5.7%; monitor FPG at least weekly for the first 8 weeks, then at least once every 4 weeks and as clinically indicated thereafter; assess renal function and lipids at baseline; monitor for signs and symptoms of severe cutaneous reactions, pneumonitis, diarrhea, and hypersensitivity throughout treatment. Hyperglycemia Management: Initiate antihyperglycemic therapy (metformin preferred) for FPG ≥160 mg/dL do not interrupt alpelisib for Grade 1–2 hyperglycemia manageable with antidiabetic agents; withhold alpelisib for FPG ≥500 mg/dL or symptomatic hyperglycemia uncontrolled with maximum antidiabetic therapy; permanently discontinue for recurrent or uncontrolled Grade 4 hyperglycemia. |
| Primary Indications | HR+/HER2-NEGATIVE PIK3CA-MUTATED METASTATIC BREAST CANCER: Alpelisib in Combination with Fulvestrant for PIK3CA-Mutated HR+/HER2− Advanced or Metastatic Breast Cancer (SOLAR-1): Alpelisib 300 mg once daily orally in combination with fulvestrant 500 mg IM, for postmenopausal women and men with hormone receptor-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer who have progressed on or after endocrine-based regimens. PIK3CA mutation status must be confirmed using an approved companion diagnostic test on tumor tissue or circulating tumor DNA (ctDNA) in plasma. Based on Phase 3 SOLAR-1 (NCT02437318; PIK3CA-mutated cohort n=341): median PFS 11.0 months (alpelisib + fulvestrant) versus 5.7 months (placebo + fulvestrant); HR 0.65; 95% CI 0.50–0.85; p<0.001 (35% reduction in risk of disease progression or death); objective response rate (ORR) 26.6% versus 12.8%; median duration of response 10.4 months. FDA approval: May 24, 2019. The indication covers patients who have received prior endocrine therapy (aromatase inhibitor and/or CDK4/6 inhibitor-based regimens) and whose tumors harbor PIK3CA activating mutations as confirmed by an approved test. |
| Manufacturer / Brand | Novartis (Novartis Pharmaceuticals Corporation / Novartis AG), Headquartered in Basel, Switzerland; India-market packaging; alpelisib was developed and is commercialized globally by Novartis as Piqray in international markets and as Pivikto in India; alpelisib was discovered and developed through Novartis’s oncology research programs targeting the PI3K pathway and received first global approval by the FDA on May 24, 2019, becoming the first PI3Kα inhibitor approved for the treatment of PIK3CA-mutated HR+/HER2− advanced breast cancer; Novartis is a global leader in precision oncology targeted therapies across breast cancer, lung cancer, leukemia, and other malignancies |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). Store in the original container tightly closed. Protect from moisture. Keep out of the reach of children. Alpelisib film-coated tablets do not require refrigerated cold-chain storage, which simplifies international shipping logistics compared to injectable biologics; however, tablets must be protected from excessive heat, humidity, and moisture exposure during transport and storage. Do not use if the packaging is damaged or if the product appears tampered with. Discard any unused tablets after the expiry date printed on the pack. |
How Pivikto (Alpelisib) Works: Selective PI3Kα Inhibition, PIK3CA Mutation Targeting, AKT/mTOR Pathway Suppression, and Endocrine Therapy Resistance Reversal in HR+/HER2-Negative Breast Cancer
Alpelisib (Pivikto) exerts its antitumor activity through highly selective, competitive inhibition of the alpha isoform of class I phosphatidylinositol 3-kinase (PI3Kα), the lipid kinase encoded by the PIK3CA gene and the most commonly mutated oncogenic driver in hormone receptor-positive (HR+), HER2-negative breast cancer. PI3Kα is a heterodimeric enzyme consisting of the p110α catalytic subunit (encoded by PIK3CA) and the p85 regulatory subunit; in normal cells, PI3Kα activation is tightly regulated by upstream growth factor receptor tyrosine kinases (RTKs) and G-protein coupled receptors, and leads to controlled phosphorylation of the lipid second messenger phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the inner leaflet of the plasma membrane.
PIP3 serves as a docking platform for the AKT serine/threonine kinase and its upstream activating kinase PDK1; AKT is then activated by dual phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2), enabling it to phosphorylate a broad range of substrates that collectively drive cell cycle progression, protein synthesis, cell survival, and inhibition of pro-apoptotic signaling including TSC1/2 (activating mTORC1 and S6K1/4E-BP1-driven protein synthesis), FOXO transcription factors (promoting cell survival and endocrine therapy resistance), and MDM2 (attenuating p53-mediated apoptosis). Alpelisib occupies the ATP-binding pocket within the p110α catalytic subunit of PI3Kα with high selectivity for the alpha isoform over the beta, gamma, and delta isoforms, blocking the phosphotransfer reaction that generates PIP3 from PIP2 and thereby collapsing AKT activation and all downstream mTOR pathway signaling in PI3Kα-dependent tumor cells.
PIK3CA activating mutations the most common of which include helical domain mutations E542K and E545K, and kinase domain mutation H1047R, though over 30 recurrent activating mutations across exons 1, 4, 7, 9, and 20 are recognized render the p110α catalytic subunit constitutively active independent of upstream growth factor receptor signaling, causing persistent PIP3 generation and constitutive AKT/mTOR pathway activation that drives tumor cell proliferation and survival even in the absence of ligand stimulation. This constitutive PI3K pathway activation contributes directly to endocrine therapy resistance: in HR+/HER2− breast cancer, PI3Kα-driven AKT activation can phosphorylate and activate estrogen receptor alpha (ERα) in a ligand-independent manner, bypass estrogen deprivation by aromatase inhibitors, and downregulate ER-driven transcriptional programs that confer sensitivity to fulvestrant; PIK3CA-mutated tumors are therefore more likely to progress on aromatase inhibitor or fulvestrant monotherapy than PIK3CA-wild-type tumors.
Alpelisib’s PI3Kα inhibition directly targets this resistance mechanism: by suppressing constitutive PI3K/AKT/mTOR pathway activity, alpelisib restores ER dependency in PIK3CA-mutated HR+/HER2− tumor cells and re-sensitizes them to fulvestrant-mediated ER degradation, providing mechanistic synergy for the alpelisib plus fulvestrant combination that is validated by the SOLAR-1 trial’s statistically significant PFS improvement (HR 0.65; median PFS 11.0 versus 5.7 months; p<0.001) exclusively in the PIK3CA-mutated patient cohort and not in the PIK3CA-wild-type cohort (HR 0.85; p=0.37) confirming that the clinical benefit of alpelisib is strictly biomarker-restricted to tumors with confirmed PIK3CA mutations.
The alpelisib-mediated hyperglycemia adverse effect the most clinically significant safety consideration is a pharmacodynamic consequence of on-target PI3Kα inhibition in insulin-signaling tissues: PI3Kα is essential for insulin receptor-stimulated AKT activation in skeletal muscle, liver, and adipose tissue; alpelisib-mediated PI3Kα suppression in these normal tissues induces compensatory hyperinsulinemia and reduced insulin-stimulated glucose uptake, producing dose-dependent hyperglycemia that is managed with antihyperglycemic agents, most effectively metformin, without compromising the antitumor activity of alpelisib. Visit the Mediaid Pharmacy breast cancer medicines collection for the complete PIK3CA-targeted and HR+/HER2− breast cancer therapy portfolio.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Pivikto 150 MG (Alpelisib)
Mediaid Pharmacy is a Dhaka-based supplier of specialty targeted oncology, breast cancer, HR-positive metastatic breast cancer, and rare disease medicines with worldwide shipping to patients, oncology departments, infusion units, metastatic breast cancer treatment programs, hospital pharmacies, oncology day units, patient access programs, and international distributors across all regions. Pivikto 150 MG (Alpelisib), manufactured by Novartis in India-market packaging, is supplied as 150 mg film-coated tablets, 28 tablets per pack, with pricing quotations, stock confirmation, full product documentation, shipping arrangements, and end-to-end international delivery tracking for every order.
The procurement planning significance of the 28-tablet pack format is directly tied to alpelisib’s continuous daily oral dosing architecture: at the recommended dose of 300 mg once daily (two 150 mg tablets per day), two 28-tablet packs per patient per 28-day cycle are required; for institutions managing multiple patients simultaneously across different treatment cycles, monthly procurement is calculated by multiplying the number of active alpelisib-receiving patients by two packs per 28-day month.
PIK3CA-mutated HR+/HER2− metastatic breast cancer programs managing long-duration alpelisib maintenance therapy until disease progression; HR-positive metastatic breast cancer centers sourcing alpelisib for post-aromatase inhibitor or post-CDK4/6 inhibitor PIK3CA-mutated patients; hospital formulary procurement departments co-sourcing Pivikto 150 MG with fulvestrant and other targeted oncology medicines; and individual patients and families sourcing alpelisib for PIK3CA-mutated HR-positive metastatic breast cancer treatment can contact the Mediaid Pharmacy team through WhatsApp, phone, or email for Pivikto 150 MG stock availability, current pricing, shipping options, and international delivery timelines.
Why Choose Pivikto 150 MG (Alpelisib) from Mediaid Pharmacy?
Pivikto (Alpelisib) from Novartis delivers the validated PI3Kα-selective inhibition mechanism of the first and only FDA-approved PI3Kα inhibitor for breast cancer a targeted oral therapy with regulatory approval based on the landmark SOLAR-1 Phase 3 trial that produced the first statistically significant PFS improvement ever demonstrated by targeting the PI3K pathway in PIK3CA-mutated HR+/HER2− metastatic breast cancer, addressing a molecular subtype representing approximately 40% of all HR+/HER2− advanced breast cancer patients supplied as 150 mg film-coated oral tablets in India-market packaging, enabling convenient once-daily oral self-administration without the IV infusion infrastructure required for injectable biologics. Alpelisib is pharmacologically and clinically distinguished across the HR+/HER2− metastatic breast cancer treatment landscape by four evidence-based attributes.
First, alpelisib is the only PI3Kα inhibitor to demonstrate a statistically significant PFS benefit in PIK3CA-mutated HR+/HER2− advanced breast cancer in a Phase 3 trial the SOLAR-1 trial’s PIK3CA-mutated cohort primary endpoint analysis (HR 0.65; 95% CI 0.50–0.85; p<0.001) achieved a median PFS of 11.0 months versus 5.7 months with placebo plus fulvestrant a 5.3-month absolute improvement in median PFS representing a 35% reduction in the risk of disease progression or death in a treatment setting (endocrine therapy-resistant PIK3CA-mutated HR+/HER2− metastatic breast cancer) where the median PFS with fulvestrant monotherapy was historically approximately 4–6 months; this PFS benefit was accompanied by an objective response rate (ORR) of 26.6% versus 12.8%, establishing alpelisib plus fulvestrant as the standard of care combination for the PIK3CA-mutated molecular subgroup after endocrine therapy progression.
Second, alpelisib’s PI3Kα isoform selectivity inhibiting p110α with substantially greater potency than p110β, p110γ, or p110δ is the mechanistic basis for its differentiated clinical tolerability profile compared to pan-PI3K inhibitors: by sparing PI3Kδ (which is essential for B-cell and T-cell function), alpelisib does not produce the severe immunosuppression, pneumonitis risk, or colitis associated with PI3Kδ inhibitors such as idelalisib; by sparing PI3Kβ (which mediates platelet aggregation), alpelisib avoids the thrombocytopenia and bleeding risk associated with pan-PI3K beta-sparing agents; this isoform selectivity produces a toxicity profile dominated by hyperglycemia (pharmacodynamic on-target effect in insulin-signaling tissues), diarrhea, and rash toxicities that are clinically manageable with antihyperglycemic agents, antidiarrheal therapy, and dermatologic management respectively, without the severe immunotoxicity limitations of less selective PI3K inhibitors.
Third, alpelisib’s oral once-daily tablet formulation enables patient self-administration at home without requiring IV infusion center visits for the alpelisib component of the regimen, contrasting with injectable anti-HER2 therapies (pertuzumab, trastuzumab) or CDK4/6 inhibitor regimens requiring frequent hospital attendance the oral nature of alpelisib is particularly clinically meaningful in resource-limited settings, outpatient oncology programs, and patient populations where travel to infusion centers is a treatment adherence barrier.
Fourth, alpelisib’s PIK3CA companion diagnostic-linked prescribing model requiring pre-treatment PIK3CA mutation testing by an approved test as a mandatory eligibility criterion ensures that alpelisib is administered only to patients whose tumors are biologically responsive to PI3Kα inhibition, maximizing clinical benefit-risk ratio at the patient level and enabling precision oncology treatment decisions guided by molecular biomarker profiling rather than histological subtype alone.
To source the complete range of PIK3CA-targeted breast cancer therapies, HR-positive breast cancer medicines, and oncology medicines, visit the Mediaid Pharmacy breast cancer medicines portfolio, the oncology medicines collection, and the Novartis oncology medicines range, and contact the team for a personalized quotation and international shipping confirmation.
Frequently Asked Questions About Pivikto 150 MG (Alpelisib)
What is Pivikto 150 MG (Alpelisib) used for?
Pivikto 150 MG (Alpelisib) is an oral PI3Kα inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), HER2-negative (HER2−), PIK3CA-mutated, advanced or metastatic breast cancer who have progressed on or after endocrine-based therapy. SOLAR-1 (Phase 3, NCT02437318; PIK3CA-mutated cohort n=341): alpelisib 300 mg once daily plus fulvestrant 500 mg IM versus placebo plus fulvestrant in HR+/HER2− PIK3CA-mutated advanced breast cancer patients who had received prior endocrine therapy (aromatase inhibitor ± CDK4/6 inhibitor); median PFS 11.0 months versus 5.7 months (HR 0.65; 95% CI 0.50–0.85; p<0.001; 35% reduction in risk of disease progression or death); ORR 26.6% versus 12.8%; median duration of response 10.4 months; FDA approval May 24, 2019. PIK3CA mutation testing is mandatory before initiating alpelisib only patients with confirmed PIK3CA-mutated tumors (by tissue biopsy or ctDNA liquid biopsy using an approved companion diagnostic) are eligible. Premenopausal and perimenopausal women receiving alpelisib must also receive concurrent GnRH agonist therapy. Pivikto 150 MG, manufactured by Novartis in India-market packaging, is available through Mediaid Pharmacy with worldwide shipping to patients and HR-positive breast cancer treatment programs globally.
What is the generic name of Pivikto?
The generic name (International Nonproprietary Name, INN) of Pivikto is alpelisib (also designated BYL719 during preclinical and clinical development by Novartis). Alpelisib is a selective, orally bioavailable small-molecule inhibitor of the alpha isoform of class I phosphatidylinositol 3-kinase (PI3Kα), the lipid kinase encoded by the PIK3CA gene. Its mechanism of action competitive inhibition of the ATP-binding pocket of the p110α catalytic subunit of PI3Kα, blocking PIP2-to-PIP3 phosphorylation and suppressing AKT/mTOR downstream signaling targets the constitutively active PI3Kα produced by oncogenic PIK3CA mutations (most commonly E542K, E545K in the helical domain and H1047R in the kinase domain) that drive approximately 38–40% of HR+/HER2− advanced breast cancers. Alpelisib is mechanistically distinct from all other approved breast cancer PI3K pathway agents: everolimus (Afinitor) is an mTOR inhibitor acting downstream of PI3K/AKT; CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) target cell cycle kinases rather than the PI3K pathway; capivasertib (Truqap) is an AKT inhibitor; inavolisib is a PI3Kα inhibitor and PIK3CA mutant-selective degrader in clinical development. Alpelisib is the only PI3Kα-selective inhibitor with current FDA approval in breast cancer. Developed and commercialized by Novartis, alpelisib received FDA approval on May 24, 2019 and is sold in India as Pivikto. Mediaid Pharmacy distributes Pivikto 150 MG Alpelisib globally with worldwide shipping to patients, oncology programs, and hospital pharmacies.
What are the side effects of Pivikto (Alpelisib)?
The most clinically significant adverse effects of alpelisib are hyperglycemia, severe cutaneous adverse reactions (SCARs), diarrhea, pneumonitis, and hypersensitivity reactions. Hyperglycemia is the most common serious adverse reaction: all-grade hyperglycemia occurred in 63.7% of patients receiving alpelisib in SOLAR-1; Grade 3 (FPG 250–499 mg/dL) and Grade 4 (FPG ≥500 mg/dL) hyperglycemia occurred in approximately 36.6% requiring mandatory FPG and HbA1c monitoring before and during treatment, with antihyperglycemic therapy (preferably metformin) initiated for FPG ≥160 mg/dL. Severe Cutaneous Adverse Reactions (SCARs): Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, and DRESS have been reported permanently discontinue alpelisib at first sign of a severe cutaneous reaction; rash (all grades) occurred in 52.1% of patients in SOLAR-1. Diarrhea: 57.7% all-grade; Grade 3 diarrhea occurred in approximately 6.7% manage with antidiarrheal agents and alpelisib dose modification as needed. Nausea: 45.2% (taking alpelisib with food reduces nausea). Fatigue: 42.0%. Decreased appetite: 35.9%. Stomatitis: 29.9%. Vomiting: 27.5%. Weight decrease: 26.8%. Pneumonitis: including fatal cases; permanently discontinue alpelisib for Grade 3 or 4 pneumonitis; withhold for Grade 2 and evaluate. Hypersensitivity reactions: including anaphylaxis and anaphylactic shock permanently discontinue alpelisib. All patients initiating Pivikto (Alpelisib) should have baseline FPG, HbA1c, renal function, and hepatic function assessed, PIK3CA mutation confirmed by an approved diagnostic, and treatment initiated under the supervision of a qualified oncologist experienced in managing targeted therapy toxicities.
Do I need a PIK3CA mutation test before receiving Pivikto (Alpelisib)?
Yes. PIK3CA mutation testing using an approved companion diagnostic is a mandatory prerequisite before initiating Pivikto (Alpelisib). Alpelisib is indicated exclusively for patients with HR+/HER2− advanced or metastatic breast cancer whose tumors harbor activating PIK3CA mutations patients with PIK3CA-wild-type tumors did not benefit from alpelisib in the SOLAR-1 trial (HR 0.85; 95% CI 0.58–1.25; p=0.37 in the wild-type cohort). Two FDA-approved companion diagnostic tests are approved to select patients for alpelisib treatment: (1) the therascreen PIK3CA RGQ PCR Kit (Qiagen), which detects PIK3CA mutations in tumor tissue (FFPE) or cell-free circulating tumor DNA (ctDNA) in plasma (liquid biopsy) the plasma-based option allows PIK3CA testing without requiring a new tumor biopsy, using a blood draw; and (2) the FoundationOne CDx (Foundation Medicine), a comprehensive genomic profiling panel that detects PIK3CA mutations in FFPE tumor tissue alongside a broad spectrum of other clinically actionable alterations. If the plasma ctDNA test result is negative (wild-type), the treating oncologist should consider repeat testing using a tissue biopsy-based assay, since ctDNA sensitivity may be lower in patients with low tumor burden or limited circulating tumor DNA shedding. PIK3CA testing is not optional it is both a clinical and regulatory requirement for alpelisib eligibility. Patients with confirmed PIK3CA mutations should discuss alpelisib treatment options with their treating oncologist. Contact Mediaid Pharmacy for Pivikto 150 MG availability; visit the breast cancer medicines collection for PIK3CA-mutated HR+/HER2− breast cancer treatment options.
How effective is Pivikto (Alpelisib) for PIK3CA-mutated HR+/HER2-negative metastatic breast cancer?
Alpelisib demonstrated a statistically significant and clinically meaningful progression-free survival benefit in PIK3CA-mutated HR+/HER2− advanced breast cancer in the Phase 3 SOLAR-1 trial (NCT02437318) the defining Phase 3 study establishing alpelisib plus fulvestrant as the standard of care for PIK3CA-mutated HR+/HER2− metastatic breast cancer after endocrine therapy progression. SOLAR-1 randomized 572 patients with HR+/HER2− advanced breast cancer (341 in the PIK3CA-mutated cohort, 231 in the PIK3CA wild-type cohort) who had progressed on or after endocrine-based therapy to alpelisib 300 mg once daily plus fulvestrant 500 mg IM, or placebo plus fulvestrant 500 mg IM. The primary endpoint progression-free survival by local investigator assessment in the PIK3CA-mutated cohort demonstrated a median PFS of 11.0 months (alpelisib + fulvestrant) versus 5.7 months (placebo + fulvestrant) (HR 0.65; 95% CI 0.50–0.85; p<0.001), representing a 35% reduction in the risk of disease progression or death and a 5.3-month absolute improvement in median PFS. The objective response rate (ORR) in the PIK3CA-mutated cohort was 26.6% with alpelisib plus fulvestrant versus 12.8% with placebo plus fulvestrant. Critically, in the PIK3CA wild-type cohort, alpelisib did not demonstrate a statistically significant PFS benefit (HR 0.85; p=0.37) confirming that alpelisib’s clinical activity is strictly dependent on the presence of PIK3CA mutations in the tumor, validating the companion diagnostic-based patient selection requirement. The clinical benefit of alpelisib was observed across PIK3CA mutation subtypes (helical and kinase domain mutations), across prior CDK4/6 inhibitor exposure subgroups, and across both tissue-detected and plasma ctDNA-detected PIK3CA mutation populations. Pivikto 150 MG (Alpelisib) is available through Mediaid Pharmacy with worldwide shipping; visit the breast cancer medicines collection for the complete HR+/HER2-negative targeted therapy portfolio.
What is the difference between Pivikto (Alpelisib) and other PI3K or AKT pathway inhibitors for HR+ breast cancer?
Pivikto (Alpelisib) is a selective PI3Kα inhibitor that differs mechanistically, clinically, and in biomarker requirements from all other PI3K, AKT, and mTOR pathway inhibitors used in HR+/HER2− breast cancer. Everolimus (Afinitor, mTOR inhibitor): acts downstream of PI3K and AKT by inhibiting mTORC1, used in combination with exemestane for HR+/HER2− advanced breast cancer; does not require PIK3CA mutation testing; approved for a broader patient population including PIK3CA-wild-type tumors; primary toxicities are stomatitis, pneumonitis, infections, and metabolic effects hyperglycemia occurs but is less severe and predominant than with alpelisib; clinical benefit in BOLERO-2 trial: median PFS 6.9 versus 2.8 months (HR 0.43). Capivasertib (Truqap, AKT inhibitor): inhibits all three AKT isoforms (AKT1, 2, 3), approved in combination with fulvestrant for HR+/HER2− advanced breast cancer with one or more of PIK3CA/AKT1/PTEN alterations; approved for a broader biomarker-defined population beyond PIK3CA mutations alone; primary toxicities are diarrhea, rash, and hyperglycemia; CAPItello-291 trial: median PFS 7.3 versus 3.1 months in the biomarker-selected population (HR 0.50). Alpelisib (Pivikto) versus everolimus and capivasertib: alpelisib is specifically indicated for PIK3CA mutation-confirmed patients only (not AKT1 mutations or PTEN loss), reflecting its upstream, isoform-selective mechanism; alpelisib’s most distinctive toxicity is severe hyperglycemia (Grade 3–4: ~37%), which is higher than that of everolimus or capivasertib and requires mandatory pre-treatment glycemic assessment. Visit the Mediaid Pharmacy oncology medicines collection for the complete PI3K pathway and HR+ breast cancer targeted therapy portfolio, including alpelisib (Pivikto), everolimus, and other oncology medicines available with worldwide shipping.
Is Pivikto (Alpelisib) safe during pregnancy or while breastfeeding?
Pivikto (Alpelisib) can cause fetal harm based on its mechanism of action and nonclinical reproductive toxicology findings alpelisib should not be used during pregnancy. PI3K/AKT/mTOR pathway signaling is essential for normal fetal development, placentation, and organogenesis; inhibition of PI3Kα activity by alpelisib is expected to disrupt these critical developmental processes. Nonclinical animal reproductive toxicology studies demonstrated embryotoxicity and fetotoxicity at clinically relevant exposures. Contraception requirement: females of reproductive potential must use effective contraception during alpelisib treatment and for 1 week after the last dose, reflecting alpelisib’s shorter plasma half-life compared to biologic agents; males with female partners of reproductive potential should use effective contraception during treatment and for 1 week after the last dose. Verify pregnancy status with a pregnancy test before initiating Pivikto in all females of reproductive potential. Alpelisib should be immediately discontinued if pregnancy is confirmed during treatment. Breastfeeding: there are no data on the presence of alpelisib in human breast milk or its effects on the breastfed infant or milk production; because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during alpelisib treatment and for 1 week after the last dose. Fertility: nonclinical studies suggest alpelisib may impair female fertility based on effects on the estrous cycle; the reversibility of these effects has not been established. All aspects of reproductive planning, contraceptive requirements, and fertility counseling should be discussed with the treating oncologist before initiating alpelisib therapy.
Can I order Pivikto 150 MG (Alpelisib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Pivikto 150 MG (Alpelisib), film-coated tablets, 28 tablets per pack, manufactured by Novartis in India-market packaging, to patients, HR+/HER2-negative metastatic breast cancer oncology departments, PIK3CA-mutated breast cancer treatment programs, hospital pharmacies, oncology day units, patient access programs, and healthcare providers globally. Pivikto 150 MG tablets do not require refrigerated cold-chain shipping (unlike injectable biologics), which simplifies international logistics tablets are shipped with temperature-protective packaging appropriate for the destination country’s climate conditions. Contact Mediaid Pharmacy via WhatsApp, phone, or email at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, shipping options, and international delivery details for your country. Prescription documentation and PIK3CA companion diagnostic confirmation are required for alpelisib dispensing in accordance with applicable regulatory requirements. For the complete portfolio of Novartis oncology medicines available with worldwide shipping, visit the Mediaid Pharmacy Novartis medicines page.
Order Pivikto 150 MG (Alpelisib) with Worldwide Shipping
Phone / WhatsApp: +8801773428128 | Email: info@mediaidpharmacy.com



